secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001628280-24-010790
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports $257.8M net loss for FY2023; cash runway into Q3 2024
---------------------------------------------------------------------

- Net loss $257.8M ($1.48/share) on revenue $176.2M (up 58% YoY on Biogen termination).
- Cash $81.0M as of Dec 31, 2023; expects funding into Q3 2024 without additional capital.
- STAC-BBB capsid showed 700-fold higher brain transduction vs AAV9 in NHPs; pain IND Q4 2024.
- Fabry drug aligned with FDA on abbreviated approval pathway; EMA PRIME granted; seeking partner.
- Wind down of French ops (93 roles); 2024 GAAP opex guidance $145–165M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/0001628280-24-010790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/sgmo-20240313.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-010790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer